

# Rahul S Dalal

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9394541/publications.pdf>

Version: 2024-02-01

18  
papers

212  
citations

1163117

8  
h-index

1058476

14  
g-index

18  
all docs

18  
docs citations

18  
times ranked

302  
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 Vaccination Intent and Perceptions Among Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1730-1732.e2.	4.4	50
2	Predictors of Ustekinumab Failure in Crohn's Disease After Dose Intensification. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1294-1301.	1.9	31
3	Predictors and Outcomes of Ustekinumab Dose Intensification in Ulcerative Colitis: A Multicenter Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2399-2401.e4.	4.4	23
4	Real-World Comparison of Tofacitinib vs Ustekinumab Among Bio-Exposed Patients With Ulcerative Colitis: A Propensity Score Analysis. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1694-1697.	1.9	19
5	Diagnosis and management of <i>Clostridioides difficile</i> infection in patients with inflammatory bowel disease. <i>Current Opinion in Gastroenterology</i> , 2021, 37, 336-343.	2.3	18
6	Hospitalization Outcomes for Inflammatory Bowel Disease in Teaching vs Nonteaching Hospitals. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1974-1982.	1.9	17
7	Exposure to Intravenous Opioids Is Associated With Future Exposure to Opioids in Hospitalized Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2269-2278.e3.	4.4	15
8	A User-Friendly Prediction Tool to Identify Colectomy Risk in Patients With Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1550-1558.	1.9	10
9	Outcomes of Standard and Intensified Dosing of Ustekinumab for Chronic Pouch Disorders. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 146-149.	1.9	8
10	Preadmission Cannabis Use Is Positively Correlated With Inpatient Opioid Dose Exposure in Hospitalized Patients With Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 500-506.	1.9	7
11	A Multimodal Intervention Using Nonopioid Analgesics Is Associated With Reduced Intravenous Opioid Exposure Among Hospitalized Patients With Inflammatory Bowel Diseases. <i>American Journal of Gastroenterology</i> , 2020, 115, 1474-1485.	0.4	6
12	Ustekinumab Dose Optimization in Crohn Disease: One Size Does Not Fit All. <i>Inflammatory Bowel Diseases</i> , 2021, 27, e70-e70.	1.9	4
13	Comparative Long-Term Drug Survival of Vedolizumab, Adalimumab, and Infliximab in Biologic-Naïve Patients with Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2023, 68, 223-232.	2.3	3
14	Two Strikes but Not Out: Deep Remission of Ulcerative Colitis with Ustekinumab After Primary Non-response to Infliximab and Vedolizumab. <i>Digestive Diseases and Sciences</i> , 2021, 66, 733-737.	2.3	1
15	Superiority Complex: Do Teaching Hospitals Provide Inferior Care for IBD Patients?. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2137-2139.	2.3	0
16	Fecal Microbiota Transplantation for Chronic Pouchitis: Promising Novel Therapeutic or Lost Cause?. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1873-1875.	1.9	0
17	Endoscopy Is Not Associated with Infectious Adverse Events After Hematopoietic Cell Transplantation: A Retrospective Cohort Study. <i>Digestive Diseases and Sciences</i> , 2021, , 1.	2.3	0
18	Author Spotlight: Rahul S. Dalal. <i>Digestive Diseases and Sciences</i> , 2021, 66, 738-738.	2.3	0